Trial of Miltuximab in Prostate, Other Cancers Gets Nod to Enroll Additional Patients July 13, 2017 The first-in-human clinical trial assessing the safety and tolerability of Miltuximab (MIL-38) — a radiolabeled antibody designed to image prostate, bladder, and pancreatic cancer — is proceeding to its second part, according to Minomic International.Read more.Source: Prostate Cancer News Today Prostate Cancer News
The first-in-human clinical trial assessing the safety and tolerability of Miltuximab (MIL-38) — a radiolabeled antibody designed to image prostate, bladder, and pancreatic cancer — is proceeding to its second part, according to Minomic International.Read more.Source: Prostate Cancer News Today
